Search

Your search keyword '"Simone Lubowitzki"' showing total 2 results
Start Over Author "Simone Lubowitzki" Publisher american association for cancer research (aacr)
2 results on '"Simone Lubowitzki"'

1. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Philipp B. Staber, Berend Snijder, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Niklas Zojer, Christoph C. Zielinski, Dominik Wolf, Cora Waldstein, Stefan Vogt, Katrina Vanura, Emiel van der Kouwe, Peter Valent, Renate Thalhammer, Ismet Srndic, Wolfgang R. Sperr, Cathrin Skrabs, Christian Sillaber, Edgar Selzer, Ilse Schwarzinger, Ann-Sofie Schmolke, Ana-Iris Schiefer, Julius Salamon, Reinhard Ruckser, Robin Ristl, Markus Raderer, Gerald W. Prager, Edit Porpaczy, Alexander Pichler, Michael Panny, Leopold Öhler, Katharina Ocko, Thomas Noesslinger, Peter Neumeister, Leonhard Müllauer, Katsuhiro Miura, Olaf Merkel, Elisabeth Menschel, Marius E. Mayerhoefer, Simone Lubowitzki, Trang Le, Stefan Kubicek, Gerhard Krajnik, Nikolaus Krall, Barbara Kiesewetter, Lukas Kenner, Lukas Kazianka, Ulrich Jaeger, Georg Hopfinger, Mir Alireza Hoda, Daniel Heintel, Tim Heinemann, Alexander W. Hauswirth, Bernd Lorenz Hartmann, Marcus Hacker, Wolfgang Gstöttner, Hildegard T. Greinix, Klaus Geissler, Alexander Gaiger, Maurizio Forte, Verena Felsleitner-Hauer, Ruth Exner, Harald Esterbauer, Martin Erl, Ruth Eichner, Sandra Eder, Michael Bergmann, Günther Bayer, Gregory I. Vladimer, Tea Pemovska, and Christoph Kornauth

Abstract

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers.Significance:This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer.See related commentary by Letai, p. 290.This article is highlighted in the In This Issue feature, p. 275

Published
2023
Full Text
View/download PDF

2. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, and Ismet Srndic

Subjects
Oncology, Drug, 0303 health sciences, medicine.medical_specialty, business.industry, media_common.quotation_subject, Cancer, Disease, Drug profiling, Precision medicine, medicine.disease, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Personalized medicine, Personalized therapy, business, 030304 developmental biology, media_common
Abstract

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. Significance: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer. See related commentary by Letai, p. 290. This article is highlighted in the In This Issue feature, p. 275

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results